Anti-Sm Antibody, Damage Index, and Corticosteroid Use Are Associated with Cardiac Involvement in Systemic Lupus Erythematosus: Data from a Prospective Registry Study
- PMID: 32476300
- PMCID: PMC7261696
- DOI: 10.3346/jkms.2020.35.e139
Anti-Sm Antibody, Damage Index, and Corticosteroid Use Are Associated with Cardiac Involvement in Systemic Lupus Erythematosus: Data from a Prospective Registry Study
Abstract
Background: Disease-specific factors that predispose patients to diverse cardiac diseases in systemic lupus erythematosus (SLE) have been established. The aim of this study was to identify risk factors for cardiac involvement in patients with SLE drawn from the Korean Lupus Network (KORNET) registry.
Methods: A total of 437 patients with SLE recruited from the KORNET registry were included in the analysis. The Cox proportional hazard model was used to identify risk factors for the development of cardiac involvement during the follow-up period. The hazard ratios for risk factors of cardiac involvement were assessed using Kaplan-Meier curves and log-rank test.
Results: Of 437 patients with SLE, 12 patients (2.7%) developed new cardiac involvement during a median follow-up period of 47.6 months. Frequencies in men and in patients with anti-Sm antibody, anti-Ro antibody, and at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) score in patients with cardiac involvement were higher, compared to those without cardiac involvement (P < 0.001, P = 0.026, P = 0.015, and P < 0.001, respectively). Men gender, older age, anti-Sm antibody, SDI, and corticosteroid dosage were potent predictors for cardiac involvement in patients with SLE in the determination of risk factors for cardiac involvement. Men, anti-Sm antibody positivity, and SDI ≥ 1 increased incidence rates of cardiac involvement for (P < 0.001, P = 0.036, and P < 0.001, respectively).
Conclusion: The results of this study reveal that SLE-related factors such as anti-Sm antibody, SDI, and corticosteroid dosage at baseline are risk factors for cardiac involvement in SLE.
Keywords: Autoimmunity; Cardiovascular Disease; Steroid; Systemic Lupus Erythematous.
© 2020 The Korean Academy of Medical Sciences.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Figures
Similar articles
-
Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry.J Rheumatol. 2017 Apr;44(4):452-458. doi: 10.3899/jrheum.160900. J Rheumatol. 2017. PMID: 28298561
-
Self-Reported Physical Activity Is Associated with Lupus Nephritis in Systemic Lupus Erythematosus: Data from KORean Lupus Network (KORNET) Registry.Yonsei Med J. 2018 Sep;59(7):857-864. doi: 10.3349/ymj.2018.59.7.857. Yonsei Med J. 2018. PMID: 30091319 Free PMC article.
-
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.Arthritis Care Res (Hoboken). 2012 Jan;64(1):132-7. doi: 10.1002/acr.20648. Arthritis Care Res (Hoboken). 2012. PMID: 21954226
-
Diagnostic criteria for systemic lupus erythematosus: a critical review.J Autoimmun. 2014 Feb-Mar;48-49:10-3. doi: 10.1016/j.jaut.2014.01.004. Epub 2014 Jan 21. J Autoimmun. 2014. PMID: 24461385 Review.
-
Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus.Arthritis Care Res (Hoboken). 2018 Nov;70(11):1621-1629. doi: 10.1002/acr.23531. Arthritis Care Res (Hoboken). 2018. PMID: 29409150
Cited by
-
Coexistent pleural effusion is found to be associated with aggravated subclinical myocardial injury in systemic lupus erythematous using cardiovascular magnetic resonance imaging.Front Immunol. 2024 Nov 25;15:1504624. doi: 10.3389/fimmu.2024.1504624. eCollection 2024. Front Immunol. 2024. PMID: 39654879 Free PMC article.
-
Peripheral CD4 +CD8 + double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus.J Biomed Res. 2022 Sep 28;37(1):59-68. doi: 10.7555/JBR.36.20220094. Online ahead of print. J Biomed Res. 2022. PMID: 36625011 Free PMC article.
-
Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.Nat Rev Rheumatol. 2022 May;18(5):286-300. doi: 10.1038/s41584-022-00770-y. Epub 2022 Apr 7. Nat Rev Rheumatol. 2022. PMID: 35393604 Review.
-
Coronary Artery Disease in Systemic Lupus Erythematosus: What Do the Facts Say?Cureus. 2023 Jan 6;15(1):e33449. doi: 10.7759/cureus.33449. eCollection 2023 Jan. Cureus. 2023. PMID: 36751191 Free PMC article. Review.
-
A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis.Rheumatol Int. 2025 May 10;45(6):139. doi: 10.1007/s00296-025-05894-4. Rheumatol Int. 2025. PMID: 40347239 Free PMC article. Review.
References
-
- Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384(9957):1878–1888. - PubMed
-
- Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. - PubMed
-
- Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3(6):423–453. - PubMed
-
- Aviña-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res (Hoboken) 2017;69(6):849–856. - PubMed
-
- Tselios K, Gladman DD, Su J, Ace O, Urowitz MB. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: a longterm prospective study. J Rheumatol. 2017;44(12):1841–1849. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials